What are ASCO recommendations for second-line therapy of stage IV non–small cell lung cancer (NSCLC) in patients with BRAF mutations?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

For patients with BRAF mutations, recommendations include the following:

  • Offer atezolizumab, nivolumab, or pembrolizumab (if PDL-1 TPS >1%), unless first-line therapy included an immune checkpoint inhibitor

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!